{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:48:28Z","timestamp":1788961708270,"version":"build-2803163510"},"reference-count":25,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Venous thromboembolism (VTE) is a major cardiovascular complication in cancer patients and the leading cause of morbidity and mortality. The aim of the study was to evaluate the incidence, timing, clinical predictors, and management of VTE in patients with breast cancer (BC), undergoing oncological therapy, and to propose a risk-adapted strategy for thrombosis monitoring and prevention. Methods: In this retrospective single-center study, 116 women with histologically confirmed BC (stages I\u2013IV) treated between 2021 and 2024 were included. Patients were divided according to the occurrence of objectively confirmed VTE. Clinical characteristics, comorbidities, laboratory parameters, cancer-related factors, and treatment modalities were analyzed. Univariate and multivariate logistic regression analyses were performed to identify independent predictors of VTE. Results: VTE occurred in 25 patients (21.6%), predominantly within the first 12 months after cancer diagnosis. Patients who developed VTE were significantly older and more frequently had hypertension, dyslipidemia, hyperglycemia, anemia, and leukocytosis. Multivariate analysis identified age \u2265 55 years, poor performance status (ECOG \u2265 3), and elevated glucose level as independent predictors of VTE. Deep vein thrombosis of the lower and upper extremities was the most common manifestation (52%), while pulmonary embolism was present in 24% of cases, either alone or in combination (20%). Direct oral anticoagulants were the most frequently used long-term anticoagulant therapy. Conclusions: VTE is a clinically relevant and relatively frequent complication in patients with BC, particularly during the early period of anticancer treatment. Patient-related and metabolic factors play a key role in thrombosis risk, underscoring the need for individualized, risk-adapted approaches to VTE prevention and monitoring in these populations.<\/jats:p>","DOI":"10.3390\/jcm15031161","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T12:00:47Z","timestamp":1770033647000},"page":"1161","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cancer-Associated Thrombosis in Breast Cancer: Risk Factors and Personalized Management"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7973-7894","authenticated-orcid":false,"given":"Sergey","family":"Kozhukhov","sequence":"first","affiliation":[{"name":"State Institution \u201cNational Scientific Center\u201d The M.D. Strazhesko Institute of Cardiology, Clinical and Regenerative Medicine of the National Academy of Medical Sciences of Ukraine, Kyiv 03151, Ukraine"},{"name":"Cardio-Oncology Center, Kyiv 03151, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliia","family":"Dovganych","sequence":"additional","affiliation":[{"name":"State Institution \u201cNational Scientific Center\u201d The M.D. Strazhesko Institute of Cardiology, Clinical and Regenerative Medicine of the National Academy of Medical Sciences of Ukraine, Kyiv 03151, Ukraine"},{"name":"Cardio-Oncology Center, Kyiv 03151, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olha","family":"Lygyrda","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Kyiv 03022, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Smolanka","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Kyiv 03022, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Loboda","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Kyiv 03022, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergii","family":"Lyalkin","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Kyiv 03022, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12959-025-00719-7","article-title":"Cancer-associated venous thromboembolism: A comprehensive review","volume":"23","author":"Wan","year":"2025","journal-title":"Thromb. J."},{"key":"ref_2","unstructured":"National Cancer Registry of Ukraine (NCRU) (2024). Cancer in Ukraine 2022\u20132023: Incidence, mortality, prevalence and other relevant statistics. Bulletin of the National Cancer Registry of Ukraine, National Cancer Registry of Ukraine (NCRU)."},{"key":"ref_3","first-page":"8589","article-title":"Risk factors associated with venous thromboembolism in breast cancer: A narrative review","volume":"30","author":"Razouki","year":"2022","journal-title":"Support. Care Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.thromres.2021.12.025","article-title":"Contemporary breast cancer treatment-associated thrombosis","volume":"213","author":"Kirwan","year":"2022","journal-title":"Thromb. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1610383","DOI":"10.3389\/pore.2022.1610383","article-title":"Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer","volume":"28","author":"Rubovszky","year":"2022","journal-title":"Pathol. Oncol. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer: ASCO Guideline Update","volume":"41","author":"Key","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","article-title":"Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Gradishar","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"ESMO Guidelines Committee. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline","volume":"34","author":"Falanga","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1182\/bloodadvances.2021006484","article-title":"Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy","volume":"6","author":"Overvad","year":"2022","journal-title":"Blood Adv."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.3324\/haematol.2018.209114","article-title":"CAT-prediction collaborators. The Khorana score for prediction of venous thromboembolism in cancer patients: A systematic review and meta-analysis","volume":"104","author":"Mulder","year":"2019","journal-title":"Haematologica"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1253\/circj.CJ-24-0581","article-title":"Association Between White Blood Cell Counts at Diagnosis and Clinical Outcomes in Venous Thromboembolism\u2014From the COMMAND VTE Registry-2","volume":"89","author":"Ikeda","year":"2025","journal-title":"Circ. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1111\/jth.14614","article-title":"Risk factors for cancer-associated venous thromboembolism: The venous thromboembolism prevention in the ambulatory cancer clinic (VTE-PACC) study","volume":"17","author":"Douce","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"100229","DOI":"10.1016\/j.clinsp.2023.100229","article-title":"Venous thromboembolism incidence in postoperative breast cancer patients","volume":"78","author":"Maesaka","year":"2023","journal-title":"Clinics"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejim.2020.05.031","article-title":"A snapshot of cancer-associated thromboembolic disease in 2018\u20132019: First data from the TESEO prospective registry","volume":"78","year":"2020","journal-title":"Eur. J. Intern. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1182\/blood-2015-01-625582","article-title":"When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English health care data","volume":"127","author":"Walker","year":"2016","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Khan, U.T., Walker, A.J., Baig, S., Card, T.R., Kirwan, C.C., and Grainge, M.J. (2017). Venous thromboembolism and mortality in breast cancer: Cohort study with systematic review and meta-analysis. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3719-1"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/cncr.30364","article-title":"Time-dependent risk and predictors of venous thromboembolism in breast cancer patients: A population-based cohort study","volume":"123","author":"Brand","year":"2017","journal-title":"Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1161\/ATVBAHA.123.318779","article-title":"Updates in the Incidence, Pathogenesis, and Management of Cancer and Venous Thromboembolism","volume":"43","author":"Girardi","year":"2023","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Park, J.H., Ahn, S.E., Kwon, L.M., Ko, H.H., Kim, S., Suh, Y.J., Kim, H.Y., Park, K.H., and Kim, D. (2023). The Risk of Venous Thromboembolism in Korean Patients with Breast Cancer: A Single-Center Experience. Cancers, 15.","DOI":"10.3390\/cancers15123124"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccm.2018.04.001","article-title":"Clinical Probability Tools for Deep Venous Thrombosis, Pulmonary Embolism, and Bleeding","volume":"39","author":"Harder","year":"2018","journal-title":"Clin. Chest Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaccao.2024.02.001","article-title":"Cardiovascular Concerns, Cancer Treatment, and Biological and Chronological Aging in Cancer: JACC Family Series","volume":"6","author":"Ioffe","year":"2024","journal-title":"JACC Cardio Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Dr\u0103gan, A., and Dr\u0103gan, A.\u015e. (2024). Novel Insights in Venous Thromboembolism Risk Assessment Methods in Ambulatory Cancer Patients: From the Guidelines to Clinical Practice. Cancers, 16.","DOI":"10.3390\/cancers16020458"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejim.2024.08.005","article-title":"Thrombosis in breast cancer patients on cyclin-dependent kinase inhibitors: Survival impact and predictive factors. A study by the Cancer and Thrombosis Group of the Spanish Society of Medical Oncology (SEOM)","volume":"130","author":"Adoamnei","year":"2024","journal-title":"Eur. J. Intern. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"406","DOI":"10.31083\/j.rcm2511406","article-title":"Thromboembolism in Patients with Cancer: A Practical Guide to Recurrent Events","volume":"25","author":"Kozhukhov","year":"2024","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1111\/jth.14303","article-title":"Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism","volume":"16","author":"Zakai","year":"2018","journal-title":"J. Thromb. Haemost."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/3\/1161\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T12:21:55Z","timestamp":1770034915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/3\/1161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["jcm15031161"],"URL":"https:\/\/doi.org\/10.3390\/jcm15031161","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]}}}